

08/01/00
JC694 U.S. PRO

08-02-00

JC525 U.S. PRO
09/628401
08/01/00

Applicants : Kenneth Kensey, William N. Hogenauer, and Young Cho
Invention : APPARATUS AND METHODS FOR COMPREHENSIVE BLOOD ANALYSIS, INCLUDING WORK OF, AND CONTRACTILITY OF, HEART AND THERAPEUTIC APPLICATIONS AND COMPOSITIONS THEREOF

This is a Continuation-in-Part patent application which includes the following:

1. Transmittal letter in duplicate
2. Drawings – 19 sheets
3. Specification – 47 pages
4. 56 Claims – 14 pages
5. Abstract – 1 page
6. Declaration for Patent Application -- 2 pages
7. Verified Statement Claiming Small Entity Status–
(37 CFR 1.9(f) & 1.27 (b)) - Independent Inventor
8. Verified Statement Claiming Small Entity Status–
(37 CFR 1.9(f) & 1.27 (c)) - Small Business Concern
9. Assignment of Kenneth Kensey and William Hogenauer
and Recordation Sheet
10. Assignment of Young Cho and Recordation Sheet
11. Return Receipt Postcard

“Express Mail” Mailing Label No. EL 618 129 242 US

Date of Deposit **AUGUST 1, 2000**

I hereby certify that the above-identified documents
are being deposited with the United States Postal
Service “Express Mail Post Office to Addressee”
service under 37 CFR 1.10 on the date indicated above
and are addressed to the Assistant Commissioner for
Patents, Washington, D.C. 20231

Andre Steed

Andre Steed

09628401-080100

PATENT APPLICATION TRANSMITTAL LETTER

Our Docket No. V1025/20044

To The Assistant Commissioner For Patents:

Transmitted herewith for filing under 35 U.S.C. 111 and 37 CFR 1.53 is the patent application of:

Kenneth Kensey, William N. Hogenauer, and Young Cho entitled:
APPARATUS AND METHODS FOR COMPREHENSIVE BLOOD ANALYSIS, INCLUDING WORK OF, AND CONTRACTILITY OF, HEART AND THERAPEUTIC APPLICATIONS AND COMPOSITIONS THEREOF

Enclosed are:


- x 62 pages of written description, claims and abstract.
- x 19 sheets of drawings.
- x assignments (two) of the invention to Visco Technologies, Inc. by (1) Kenneth Kensey and William Hogenauer and (2) Young Cho
- x recordation sheets for each of the two assignments
- x executed declaration of the inventor(s) and power of attorney.
- ☐ certified copy of a _____ application.
- x verified statement to establish small entity status under 37 CFR 1.9(f) and 1.27(b) - Independent Inventor.
- x verified statement to establish small entity status under 37 CFR 1.9(f) and 1.27(c) - Small Business Concern.
- ☐ information disclosure statement.
- ☐ preliminary amendment.
- ☐ other: _____

CLAIMS AS FILED

	Number Filed	Number Extra	Rate	Fee
BASIC FEE			\$690.00	\$ 690.00
TOTAL CLAIMS	56 - 20 =	* 36	x 18	648.00
INDEPENDENT CLAIMS	18 - 3 =	* 15	x 78	1,170.00
MULTIPLE DEPENDENT CLAIM PRESENT			\$260.00	0

*Number Extra Must Be Zero or Larger	TOTAL	\$ 2,508.00
If Applicant has small entity status under 37 CFR 1.9 and 1.27, then divide total fee by 2 and enter amount here	SMALL ENTITY TOTAL	\$ 1,254.00

- ☒ The Commissioner is hereby authorized to charge \$1,254.00 to cover the payment of the filing fee to our **Deposit Account No. 03-0075** (duplicate attached).
- ☒ The Commissioner is hereby authorized to charge any deficiency in the payment of the required fee(s) or credit any overpayment to our **Deposit Account No. 03-0075**.
- ☐ Charge the issue fee set in 37 CFR 1.18 at the mailing of the Notice of Allowance, pursuant to 37 CFR (1.311(b)).


 Scott M. Slomowitz, Esq.
 Reg. No. 39,032
 CAESAR, RIVISE, BERNSTEIN,
 COHEN & POKOTILOV, LTD.
 12th Floor - 7 Penn Center /1635 Market Street
 Philadelphia, PA 19103-2212 (215) 567-2010

August 1, 2000
 Date

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN

Docket Number (Optional)

V1025/20044

Applicant or Patentee: Kenneth Kensey, William N. Hogenauer and Young Cho

Serial or Patent No.: _____

Filed or Issued: _____

Title: APPARATUS AND METHODS FOR COMPREHENSIVE BLOOD ANALYSIS, INCLUDING WORK OF, AND CONTRACTILITY OF, HEART AND THERAPEUTIC APPLICATIONS AND COMPOSITIONS THEREOF

I hereby declare that I am

☐ the owner of the small business concern identified below;☒ an official of the small business concern empowered to act on behalf of the concern identified below:NAME OF SMALL BUSINESS CONCERN Visco Technologies, Inc.ADDRESS OF SMALL BUSINESS CONCERN 75 E. Uwchlan AvenueExton, PA 19341

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

☒ the specification filed herewith with title as listed above.☐ the application identified above.☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

☒ no such person, concern, or organization exists.☐ each such person, concern or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Kenneth KenseyTITLE OF PERSON IF OTHER THAN OWNER PresidentADDRESS OF PERSON SIGNING 8 Hickory Lane, Chester Springs, PA 19425SIGNATURE DATE 7/27/00

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27 (b)) - INDEPENDENT INVENTOR**

DOCKET NO. V1025/20044

APPLICANT: Kenneth Kensey, William N. Hogenauer and Young Cho

SERIAL OR PATENT NO.: _____

FILED OR ISSUED: _____

TITLE: APPARATUS AND METHODS FOR COMPREHENSIVE BLOOD ANALYSIS, INCLUDING WORK OF, AND CONTRACTILITY OF, HEART AND THERAPEUTIC APPLICATIONS AND COMPOSITIONS THEREOF

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

☒ the specification filed herewith with title as listed above.

☐ the application identified above.

☐ the patent identified above.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a non-profit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed or licensed or am under an obligation under contract or law to assign, grant, convey or license any rights in the invention is listed below:

☐ No such person, concern or organization exists.

☒ Each such person, concern or organization is listed below.

Visco Technologies, Inc.
75 E. Uwchlan Avenue
Exton, PA 19341

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

I acknowledge the duty to file, in this application no patent, notification of any change in status resulting in the loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR 1.28(b)).


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Kenneth Kensey
NAME OF INVENTOR


Signature of Inventor


7/27/00
Date

William N. Hogenauer
NAME OF INVENTOR


Signature of Inventor

7/20/00
Date

Young Cho
NAME OF INVENTOR


Signature of Inventor

7/24/00
Date

09628401-000100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION FOR LETTERS PATENT

APPLICANTS : Kenneth Kensey, William N. Hogenauer, and
Young Cho

POST OFFICE ADDRESSES: 8 Hickory Lane,
Chester Springs, PA 19425

220 Jordan Drive,
Gilbertsville, PA 19525

132 Renaissance Drive,
Cherry Hill, NJ 08003

INVENTION : APPARATUS AND METHODS FOR
COMPREHENSIVE BLOOD ANALYSIS,
INCLUDING WORK OF, AND CONTRACTILITY
OF, HEART AND THERAPEUTIC APPLICATIONS
AND COMPOSITIONS THEREOF

ATTORNEYS : Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.
12th Floor, Seven Penn Center
1635 Market Street
Philadelphia, PA 19103-2212

TO ALL WHOM IT MAY CONCERN:

Be it known that we, Kenneth Kensey, William N. Hogenauer and Young Cho, all
citizens of the United States of America, residing in the city of Chester Springs, County of
Chester, Commonwealth of Pennsylvania, in the city of Gilbertsville, County of
Montgomery, Commonwealth of Pennsylvania, and in the city of Cherry Hill, County of
Camden, State of New Jersey, respectively, have made a certain new and useful invention
in a APPARATUS & METHODS FOR COMPREHENSIVE BLOOD ANALYSIS,
INCLUDING WORK OF, AND CONTRACTILITY OF, HEART AND THERAPEUTIC
APPLICATIONS AND COMPOSITIONS THEREOF of which the following is a specification.

SPECIFICATION

RELATED APPLICATIONS

This application is a Continuation-in-Part of Co-Pending Application Serial No. 09/501,856, filed February 10, 2000, which in turn is a Continuation-in-Part of Co-Pending Application Serial No. 09/439,795, filed November 12, 1999, entitled DUAL RISER/SINGLE CAPILLARY VISCOMETER, which in turn is a Continuation-in-Part of Co-Pending Application Serial No. 08/919,906, filed August 28, 1997 (now U.S. Patent No. 6,019,735, issued on February 1, 2000), entitled VISCOSITY MEASURING APPARATUS AND METHOD OF USE, all of which are assigned to the same Assignee as the present invention and all of whose entire disclosures are incorporated by reference herein.

BACKGROUND OF THE INVENTION

This invention relates generally to apparatus and methods for determining and utilizing the viscosity of the circulating blood of a living being for diagnostics and treatment, and more particularly, apparatus and methods for detecting/reducing blood viscosity, work of the heart, contractility of the heart, for detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability, lubricity of blood, and for treating different ailments, such as peripheral arterial disease.

The importance of determining the viscosity of blood is well-known. Fibrogen, Viscosity and White Blood Cell Count Are Major Risk Factors for Ischemic Heart Disease, by Yarnell et al., Circulation, Vol. 83, No. 3, March 1991; Postprandial Changes in Plasma and Serum Viscosity and Plasma Lipids and Lipoproteins After an Acute Test Meal, by Tangney, et al., American Journal for Clinical Nutrition, 65:36-40, 1997; Studies of Plasma

Viscosity in Primary Hyperlipoproteinaemia, by Leonhardt, et al., *Atherosclerosis* 28, 29-40, 1977; Effects of Lipoproteins on Plasma Viscosity, by Sepowitz, et al., *Atherosclerosis* 38, 89-95, 1981; Hyperviscosity Syndrome in a Hypercholesterolemic Patient with Primary Biliary Cirrhosis, Rosenson, et al., *Gastroenterology*, Vol. 98, No. 5, 1990; Blood Viscosity and Risk of Cardiovascular Events: the Edinburgh Artery Study, by Lowe et al., *British Journal of Hematology*, 96, 168-171, 1997; Blood Rheology Associated with Cardiovascular Risk Factors and Chronic Cardiovascular Diseases: Results of an Epidemiologic Cross-Sectional Study, by Koenig, et al., *Angiology, The Journal of Vascular Diseases*, November 1988; Importance of Blood Viscoelasticity in Arteriosclerosis, by Hell, et al., *Angiology, The Journal of Vascular Diseases*, June, 1989; Thermal Method for Continuous Blood-Velocity Measurements in Large Blood Vessels, and Cardiac-Output Determination, by Delanois, *Medical and Biological Engineering*, Vol. 11, No. 2, March 1973; Fluid Mechanics in Atherosclerosis, by Nerem, et al., *Handbook of Bioengineering*, Chapter 21, 1985.

Much effort has been made to develop apparatus and methods for determining the viscosity of blood. Theory and Design of Disposable Clinical Blood Viscometer, by Litt et al., *Biorheology*, 25, 697-712, 1988; Automated Measurement of Plasma Viscosity by Capillary Viscometer, by Cooke, et al., *Journal of Clinical Pathology* 41, 1213-1216, 1988; A Novel Computerized Viscometer/Rheometer by Jimenez and Kostic, *Rev. Scientific Instruments* 65, Vol 1, January 1994; A New Instrument for the Measurement of Plasma-Viscosity, by John Harkness, *The Lancet*, pp. 280-281, August 10, 1963; Blood Viscosity and Raynaud's Disease, by Pringle, et al., *The Lancet*, pp. 1086-1089, May 22, 1965; Measurement of Blood Viscosity Using a Conicylindrical Viscometer, by Walker et al., *Medical and Biological Engineering*, pp. 551-557, September 1976.

One reference, namely, The Goldman Algorithm Revisited: Prospective Evaluation of a Computer-Derived Algorithm Versus Unaided Physician Judgment in Suspected Acute Myocardial Infarction, by Qamar, et al., Am Heart J 138(4):705-709, 1999, discusses the use of the Goldman algorithm for providing an indicator to acute myocardial infarction. The Goldman algorithm basically utilizes facts from a patient's history, physical examination and admission (emergency room) electrocardiogram to provide an AMI indicator.

In addition, there are a number of patents relating to blood viscosity measuring apparatus and methods. See for example, U.S. Patent Nos.: 3,342,063 (Smythe et al.); 3,720,097 (Kron); 3,999,538 (Philpot, Jr.); 4,083,363 (Philpot); 4,149,405 (Ringrose); 4,165,632 (Weber, et. al.); 4,517,830 (Gunn, deceased, et. al.); 4,519,239 (Kiesewetter, et. al.); 4,554,821 (Kiesewetter, et. al.); 4,858,127 (Kron, et. al.); 4,884,577 (Merrill); 4,947,678 (Hori et al.); 5,181,415 (Esvan et al.); 5,257,529 (Taniguchi, et al.); 5,271,398 (Schlain, et al.); and 5,447,440 (Davis, et. al.).

The Smythe '063 patent discloses an apparatus for measuring the viscosity of a blood sample based on the pressure detected in a conduit containing the blood sample. The Kron '097 patent discloses a method and apparatus for determining the blood viscosity using a flowmeter, a pressure source and a pressure transducer. The Philpot '538 patent discloses a method of determining blood viscosity by withdrawing blood from the vein at a constant pressure for a predetermined time period and from the volume of blood withdrawn. The Philpot '363 patent discloses an apparatus for determining blood viscosity using a hollow needle, a means for withdrawing and collecting blood from the vein via the hollow needle, a negative pressure measuring device and a timing device. The Ringrose '405 patent discloses a method for measuring the viscosity of blood by placing a sample

of it on a support and directing a beam of light through the sample and then detecting the reflected light while vibrating the support at a given frequency and amplitude. The Weber '632 patent discloses a method and apparatus for determining the fluidity of blood by drawing the blood through a capillary tube measuring cell into a reservoir and then returning the blood back through the tube at a constant flow velocity and with the pressure difference between the ends of the capillary tube being directly related to the blood viscosity. The Gunn '830 patent discloses an apparatus for determining blood viscosity that utilizes a transparent hollow tube, a needle at one end, a plunger at the other end for creating a vacuum to extract a predetermined amount and an apertured weight member that is movable within the tube and is movable by gravity at a rate that is a function of the viscosity of the blood. The Kiesewetter '239 patent discloses an apparatus for determining the flow shear stress of suspensions, principally blood, using a measuring chamber comprised of a passage configuration that simulates the natural microcirculation of capillary passages in a being. The Kiesewetter '821 patent discloses another apparatus for determining the viscosity of fluids, particularly blood, that includes the use of two parallel branches of a flow loop in combination with a flow rate measuring device for measuring the flow in one of the branches for determining the blood viscosity. The Kron '127 patent discloses an apparatus and method for determining blood viscosity of a blood sample over a wide range of shear rates. The Merrill '577 patent discloses an apparatus and method for determining the blood viscosity of a blood sample using a hollow column in fluid communication with a chamber containing a porous bed and means for measuring the blood flow rate within the column. The Hori '678 patent discloses a method for measurement of the viscosity change in blood by disposing a temperature sensor in the

blood flow and stimulating the blood so as to cause a viscosity change. The Esvan '415 patent discloses an apparatus that detects the change in viscosity of a blood sample based on the relative slip of a drive element and a driven element, which holds the blood sample, that are rotated. The Taniguchi '529 patent discloses a method and apparatus for determining the viscosity of liquids, e.g., a blood sample, utilizing a pair of vertically-aligned tubes coupled together via fine tubes while using a pressure sensor to measure the change of an internal tube pressure with the passage of time and the change of flow rate of the blood. The Bedingham '328 patent discloses an intravascular blood parameter sensing system that uses a catheter and probe having a plurality of sensors (e.g., an O₂ sensor, CO₂ sensor, etc.) for measuring particular blood parameters in vivo. The Schlain, '398 patent discloses an intra-vessel method and apparatus for detecting undesirable wall effect on blood parameter sensors and for moving such sensors to reduce or eliminate the wall effect. The Davis '440 patent discloses an apparatus for conducting a variety of assays that are responsive to a change in the viscosity of a sample fluid, e.g., blood.

Viscosity measuring methods and devices for fluids in general are well-known. See for example, U.S. Patent Nos.: 1,810,992 (Dallwitz-Wegner); 2,343,061 (Irany); 2,696,734 (Brunstrum et al.); 2,700,891 (Shafer); 2,934,944 (Eolkin); 3,071,961 (Heigl et al.); 3,116,630 (Piros); 3,137,161 (Lewis et al.); 3,138,950 (Welty et al.); 3,277,694 (Cannon et al.); 3,286,511 (Harkness); 3,435,665 (Tzentis); 3,520,179 (Reed); 3,604,247 (Gramain et al.); 3,666,999 (Moreland, Jr. et al.); 3,680,362 (Geerdes et al.); 3,699,804 (Gassmann et al.); 3,713,328 (Aritomi); 3,782,173 (Van Vessel et al.); 3,864,962 (Stark et al.); 3,908,441 (Virloget); 3,952,577 (Hayes et al.); 3,990,295 (Renovanz et al.); 4,149,405 (Ringrose); 4,302,965 (Johnson et al.); 4,426,878 (Price et al.); 4,432,761 (Dawe); 4,616,503 (Plungis

et al.); 4,637,250 (Irvine, Jr. et al.); 4,680,957 (Dodd); 4,680,958 (Ruelle et al.); 4,750,351 (Ball); 4,856,322 (Langrick et al.); 4,899,575 (Chu et al.); 5,142,899 (Park et al.); 5,222,497 (Ono); 5,224,375 (You et al.); 5,257,529 (Taniguchi et al.); 5,327,778 (Park); and 5,365,776 (Lehmann et al.).

5 The following U.S. patents disclose viscosity or flow measuring devices, or liquid level detecting devices using optical monitoring: U.S. Patent Nos. 3,908,441 (Virloget); 5,099,698 (Kath, et. al.); 5,333,497. The Virloget '441 patent discloses a device for use in viscometer that detects the level of a liquid in a transparent tube using photodetection. The Kath '698 patent discloses an apparatus for optically scanning a rotameter flow gauge and determining the position of a float therein. U.S. Patent No. 5,333,497 (Br nd Dag A., et al.) discloses a method and apparatus for continuous measurement of liquid flow velocity of two risers by a charge coupled device (CCD) sensor.

U.S. Patent No. 5,421,328 (Bedingham) discloses an intravascular blood parameter sensing system.

A statutory invention registration, H93 (Matta, et al.) discloses an apparatus and method for measuring elongational viscosity of a test fluid using a movie or video camera to monitor a drop of the fluid under test.

The following publications discuss red blood cell deformability and/or devices used for determining such: Measurement of Human Red Blood Cell Deformability Using a Single Micropore on a Thin Si₃N₄ Film, by Ogura, et al, IEEE Transactions on Biomedical Engineering, Vol. 38, No. 8, August 1991; the Pall BPF4 High Efficiency Leukocyte Removal Blood Processing Filter System, Pall Biomedical Products Corporation, 1993.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000

A device called the "Hevimet 40" has recently been advertised at www.hevimet.freesevice.co.uk. The Hevimet 40 device is stated to be a whole blood and plasma viscometer that tracks the meniscus of a blood sample that falls due to gravity through a capillary. While the Hevimet 40 device may be generally suitable for some whole blood or blood plasma viscosity determinations, it appears to exhibit several significant drawbacks. For example, among other things, the Hevimet 40 device appears to require the use of anti-coagulants. Moreover, this device relies on the assumption that the circulatory characteristics of the blood sample are for a period of 3 hours the same as that for the patient's circulating blood. That assumption may not be completely valid. Also, due to surface alteration, the device requires cleaning after each test.

Notwithstanding the existence of the foregoing technology, a need remains for an apparatus and method for obtaining the viscosity of the blood of a living being in-vivo and over a range of shears and for the provision of such data in a short time span.

All references cited are incorporated herein by reference in their entireties.

OBJECTS OF THE INVENTION

Accordingly, it is the general object of the present invention to provide an apparatus and methods for meeting that need.

It is a further object of this invention to provide viscosity measuring apparatus and methods for determining the viscosity of circulating blood over a range of shear rates, especially at low shear rates.

It is still yet a further object of this invention to provide an apparatus and methods for determining viscosity of the circulating blood of a living being (e.g., in-vivo blood viscosity measurement) without the need to directly measure pressure, flow and volume.

It is yet another object of this invention to provide an indication of the viscosity of the circulating blood of a living being in a short span of time.

It is yet another object of this invention to provide an apparatus and methods for measuring the viscosity of the circulating blood of a living being and with minimal
5 invasiveness.

It is still yet another object of the present invention to provide an apparatus and methods for measuring the viscosity of the circulating blood of a living being that does not require the use of anti-coagulants, or other chemicals or biologically active materials.

It is still yet another object of the present invention to provide an apparatus and method for determining the work of the heart of a living being based on the measured
10 viscosity of the circulating blood of the living being.

It is still yet another object of the present invention to provide an apparatus and method for correlating well-known risk factors to a living being by using the viscosity of the circulating blood of the living being over a range of shear rates.

It is still yet another object of the present invention to provide an apparatus and method for detecting the rate of ejection of blood from the heart of a living being based on
15 the pressure pulse of the heart.

It is still yet another object of the present invention to provide a method for explaining the cause of endothelial cell dysfunction of a living being based on hemodynamics.

It is still yet another object of the present invention to provide an apparatus and method for reducing endothelial cell dysfunction in a living being which is caused by
20 oscillating flow of the circulating blood of the living being.

It is still yet another object of the present invention to provide an apparatus and methods for determining the hematocrit of the circulating blood of a living being.

It is still yet another object of the present invention to provide an apparatus and method for determining the plasma viscosity of the circulating blood of a living being.

5 It is still yet another object of the present invention to provide an apparatus and method for providing high and low blood vessel wall shear stress data.

It is another object of this invention to provide an apparatus and methods for a correlation table that correlates a blood viscosity parameter with a blood pressure parameter to a physician with indicators of high and low blood vessel wall shear stress data.

It is still yet another object of the present invention to provide an apparatus and method for determining the lubricity of the blood of a living being.

It is still yet even another object of the present invention to provide an apparatus and method for detecting the surface tension of the circulating blood of a living being.

It is still yet another object of the present invention to provide an apparatus and method for improving blood perfusion in the lower extremities of a living being.

It is still yet another object of the present invention to provide an apparatus and methods for treating low shear injury through the use of a surface tension analysis means.

It is still yet another object of the present invention to provide apparatus and methods for reducing the work of the heart.

20 It is moreover another object of the present invention to provide an apparatus and methods for reducing the viscosity of the circulating blood of a living being.

It is even yet another object of this invention to provide an apparatus and methods for determining the coagulation/clotting effects of blood.

It is still yet another object of this invention to provide an apparatus and methods for developing and testing drugs that alter a living being's blood viscosity to achieve Newtonian-type performance at high shear rates.

It is even yet another object of this invention to provide an apparatus and methods for examining the spread of different blood viscosity profiles over a range of shear rates of a living being for diagnostic and treatment purposes.

It is still further another object of this invention to provide prophylactic and therapeutic compositions for controlling at least one property of blood measured by the apparatus and methods of the invention.

It is still further another object of this invention to provide a method for administering a medication to a living being guided by blood parameter information provided by measurement methods and apparatuses of the invention.

SUMMARY OF THE INVENTION

These and other objects of the present invention are achieved by providing a method for determining the work of the heart of a living being wherein the method comprises determining the viscosity of the circulating blood of the living being.

These and other objects of the present invention are also achieved by providing a method for determining the rate of ejection of blood from the heart of a living being wherein the method comprises detecting a pressure pulse of the heart.

These and other objects of the present invention are also achieved by providing a method for reducing endothelial cell dysfunction in a living being which is caused by oscillating flow of the circulating blood of the living being. The method comprises the step of reducing the rate of ejection of the blood from the heart of the living being.

These and other objects of the present invention are also achieved by a method for reducing endothelial cell dysfunction in a living being which is caused by oscillating flow of the circulating blood of the living being. The method comprises the step of reducing the viscosity of the circulating blood of the living being.

5 These and other objects of the present invention are also achieved by a method for reducing endothelial cell dysfunction in a living being which is caused by oscillating flow of the circulating blood of the living being. The method comprises the steps of reducing the rate of ejection of the blood from the heart and reducing the viscosity of the circulating blood of the living being.

10 These and other objects of the present invention are also achieved by a method for controlling hypertension in a living being. The method comprises the step of administering the combination of β -blocker, ACE inhibitor and blood viscosity reducing drugs together to a living being experiencing hypertension.

15 These and other objects of the present invention are also achieved by a method for determining a hematocrit of blood circulating within a living being. The method comprises optically counting red blood cells in a known volume of the circulating blood where red blood cells and plasma have not been artificially separated.

20 These and other objects of the present invention are also achieved by an apparatus for determining the hematocrit of the circulating blood of a living being without having to separate red blood cells from the plasma of the circulating blood and wherein the apparatus comprises an optical analyzer.

 These and other objects of the present invention are also achieved by a method for determining a plasma viscosity of the circulating blood of a living being wherein the method

comprises analyzing a single shear rate of flowing plasma, and wherein the plasma comprises a non-centrifuged sample of the circulating blood.

These and other objects of the present invention are also achieved by an apparatus for determining the viscosity of the plasma of the circulating blood of a living being without the need to centrifuge a portion of the circulating blood of the living being and utilizing a single shear rate analyzer.

These and other objects of the present invention are also achieved by a method for estimating blood vessel wall shear stress in high and low shear areas of a blood vessel bifurcation of a living being by correlating a blood viscosity parameter with a blood pressure parameter.

These and other objects of the present invention are also achieved by a method for analyzing the viscosity of the circulating blood of a living being. The method comprises the steps of: (a) determining viscosity data of the living being's circulating blood for a plurality of shear rates over a test run time; (b) segmenting the test run time into a plurality of time segments; and (c) generating a blood viscosity profile for each of the time segments from the beginning of the test run until the end of each of the time segments.

These and other objects of the present invention are also achieved by an apparatus for automatically determining the surface tension of the circulating blood of a living being. The apparatus comprises a blood column height determinator based on capillary rise.

These and other objects of the present invention are also achieved by a method for determining whether a drug reduces or increases the surface tension of the circulating blood of a living being. The method comprising the steps of: (a) determining the surface tension of the circulating blood of a living being utilizing a blood column height determinator based

on capillary rise; (b) administering a drug to the living being; and (c) re-determining the surface tension of the circulating blood of the living being utilizing the blood column height determinator to see the change in the surface tension.

These and other objects of the present invention are also achieved by a method for improving blood perfusion to the lower extremities of a living being experiencing peripheral arterial disease. The method comprises the steps of: (a) determining the viscosity of the circulating blood of the living being over a range of shear rates; (b) reducing the viscosity of the circulating blood by administering a substance to the living being or by blood letting; and (c) re-determining the viscosity of the circulating blood of the living being over the range of shear rates to verify the reduction in the viscosity.

These and other objects of the present invention are also achieved by providing an apparatus for determining the deformability of red blood cells of the circulating blood of a living being. The apparatus comprises a plurality of tubes closely adjacent one another and each having an inner diameter different from its neighbor. Furthermore, each of the plurality of tubes has an opening exposed to a flow of circulating blood and each of the tubes being is closed at its other end for collecting red blood cells therein.

These and other objects of the present invention are also achieved by an apparatus for detecting the lubricity of the circulating blood of a living being as the blood travels through the vascular system of the living being. The apparatus comprises: a transparent tube for passing a falling column of the circulating blood of the living being; an illuminator for directing light at a portion of the transparent tube that contains a residue left by the falling column; a detector for detecting any light that passes through the transparent tube and

residue and generating corresponding detection data; and calculation means for receiving the detection data and generating a lubricity value based on the detection data.

These and other objects of the present invention are also achieved by prophylactic and therapeutic compositions and methods for controlling at least one property of blood measured by the apparatus and methods of the invention.

These and other objects of the present invention are also achieved by a method for administering a medication to a living being, said method comprising: (a) providing an apparatus according to the invention, which is adapted to measure at least one blood flow parameter of the living being selected from the group consisting of circulating blood viscosity, absolute viscosity, effective viscosity, low shear viscosity, high shear viscosity, shear rate of circulating blood, work of heart, contractility of heart, thrombogenicity, platelet aggregation, lubricity, red blood cell deformability, thixotropy, yield stress, coagulability, coagulation time, agglutination, clot retraction, clot lysis time, sedimentation rate and prothrombin rate; (b) supplying a sample of the living being's blood to the at least one apparatus; and (c) measuring the at least one blood flow parameter to determine whether and how to administer the medication to the living being, wherein the apparatus is at least one member selected from the group consisting of a circulating blood viscometer, an electronic hematocrit analyzer, a plasma viscosity analyzer, a blood lubricity detector, a red blood cell deformability analyzer and a surface tension analyzer.

These and other objects of the present invention are also achieved by an apparatus for effecting the viscosity measurement of the circulating blood in a living being. The apparatus comprises: a lumen arranged to be coupled to the vascular system of the being; a pair of tubes having respective first ends coupled to the lumen for receipt of circulating

20

20

position with respect thereto. The analyzer also is arranged for operating the valve to isolate the pair of tubes from the being's vascular system so that the position of the blood in the pair of tubes changes. The analyzer is also arranged for monitoring the blood position change in at least one of said tubes and for calculating the viscosity of the blood based thereon.

5 Furthermore, the analyzer further comprises a human perceptible indicator of the blood position change (e.g., a flashing light whose flash rate is proportional to the speed of the blood position change, or an audible sensor that emits an audible signal having an oscillation that is proportional to the speed of the blood position change).

DESCRIPTION OF THE DRAWINGS

Other objects and many of the intended advantages of this invention will be readily appreciated when the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

Fig. 1 is a block diagram of a dual riser/single capillary (DRSC) viscometer;

Fig. 1A is a functional diagram of the first embodiment of the DRSC viscometer during the viscosity test run;

Fig. 2 is a block diagram of another DRSC viscometer;

Fig. 2A is a functional diagram of the second embodiment of the DRSC viscometer during the viscosity test run;

Fig. 3A is the graphical depiction of the cardiac output of the heart of a living being;

Fig. 3B is a graphical depiction of the pressure pulse of the heart of a living being ;

Fig. 3C is a blood viscosity vs. time plot for a living being;

Fig. 3D is a graphical depiction of the pressure pulse of the heart of a living being having a first contractility, and another pressure pulse of the heart having a second increased contractility;

Fig. 3E is a graphical depiction of how the contractility of the heart of a living being can be determined from the pressure pulse curve;

Fig. 4 is a flow diagram of a portion of an artery showing a bifurcation;

Fig. 5A is an enlarged view of healthy, normal endothelial cells located along a portion of an arterial wall;

Fig. 5B is an enlarged view of dysfunctional endothelial cells, e.g., endothelial cells located along a portion of an arterial wall opposite a bifurcation;

Fig. 6 is a functional diagram of a hematocrit analyzer of the present invention;

Fig. 7 is an enlarged view of a portion of the hematocrit analyzer showing a predetermined window used in the hematocrit analysis;

Fig. 8 is an alternative lumen for use in the hematocrit analyzer;

Figs. 9A-9C together constitute the plasma viscosity analyzer;

Fig. 10 depicts a graphical representation of the respective columns of fluid in the riser tubes of either the first or second embodiment of the DRSC viscometer during the viscosity test run;

Fig. 11 depicts a graphical representation of the absolute viscosity profile versus the effective viscosity profile corresponding to Fig. 10;

Fig. 12A depicts a typical graphical representation of the absolute viscosity profile versus the effective viscosity profile for a living being;

Fig. 12B depicts a graphical representation of the absolute viscosity profile versus the effective viscosity profile for a healthy living being;

Fig. 12C depicts a graphical representation of the effective viscosity profile for a living being under test versus the effective viscosity profile of a normal, healthy individual;

Fig. 13 is a table for presenting blood pressure and blood viscosity parameters in a matrix fashion for indicating both high and low blood vessel wall shear stress data;

Fig. 14A is an enlarged view of the top of the riser having a falling blood column showing a meniscus;

Fig. 14B depicts a blood lubricity detector used in conjunction with the riser tube of Fig. 14A;

Fig. 14C depicts blood lubricity plots for several living beings under test;

Fig. 15 depicts a red blood cell deformability analyzer;

Figs. 16A-16B depict a surface tension analyzer;

Fig. 17 depicts a graphical representation of the respective columns of fluid in the riser tubes of either the first or second embodiment of the DRSC viscometer during the viscosity test run wherein the height vs. time data is segmented into a plurality of shear rate regions;

Figs. 18A and 18B are blood viscosity profiles for a patient A and a patient B, respectively, based on the various shear rate regions depicted in Fig. 17;

Fig. 19 depicts one full blood viscosity profile including the extreme high and low shear rate ranges;

Fig. 20 depicts a method for improving blood profusion in the lower extremities of a living being;

Fig. 21 depicts a method for treating low shear injury through the use of a surface tension analyzer; and

Fig. 22 depicts red blood cell bonding at both a high shear and low shear conditions.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 As stated previously, the present application is a Continuation-in-Part of Co-Pending Application Serial No. 09/501,856, filed February 10, 2000, entitled METHOD OF ANALYZING DATA FROM A CIRCULATING BLOOD VISCOMETER FOR DETERMINING ABSOLUTE AND EFFECTIVE BLOOD VISCOSITY, which in turn is a Continuation-in-Part of Co-Pending Application Serial No. 09/439,795, filed November 12, 1999, entitled DUAL RISER/SINGLE CAPILLARY VISCOMETER, both of which are assigned to the same Assignee as the present invention and whose entire disclosures are incorporated by reference herein. The apparatus disclosed in A.S.N. 09/439,795 provides the medical community the ability to observe the instantaneous circulating blood viscosity characteristic that has, up until now, not been detectable by conventional blood viscometers.

10 In particular, the apparatus disclosed in A.S.N. 09/439,795 comprises a first embodiment of a dual riser/single capillary (DRSC) viscometer shown in Figs. 1 and 1A, and a second embodiment of the DRSC viscometer shown in Figs. 2 and 2A, each of which measures the viscosity of circulating blood, including whole blood, of a living being. For purposes of the present invention, either embodiment can be used to achieve the method described herein.

20 Basically, the DRSC viscometers 20 (Fig.1) and 120 (Fig. 2) comprise a blood receiving means 22 and 122, respectively, and an analyzer/output portion 24. The patient is coupled to the DRSC viscometers 20/120 through a circulating blood conveying means

26, e.g., a needle, an IV needle, an in-dwelling catheter, etc., or any equivalent structure that can convey circulating blood from a patient to the DRSC viscometers 20/120. The analyzer/output portion 24 includes a microprocessor 58 that, among other things, calculates the circulating blood viscosity based on the information that it receives from the blood receiving means 22/122. A display 28 is also provided for presenting the viscosity information, as well as other information to the operator. The analyzer/output portion 24 may also provide this information to other suitable output means 30, such as a datalogger 32, other computer(s) 34, a printer 36, a plotter 38, remote computers/storage 40, to the Internet 42 or to other on-line services 44.

The blood receiving means 22/122 basically comprises a valve mechanism 46 coupled between a first riser tube R1 and a second riser tube R2 (Figs. 1-2), or coupled to one end of one of the riser tubes (Figs. 3-4), for controlling the input circulating blood flow into the DRSC viscometers 20/120. In addition, a capillary tube 52 of known dimensions is coupled to one of the riser tubes (e.g., as shown in Fig. 2), or is coupled between the riser tubes (e.g., as shown in Fig. 4). In general, the valve mechanism 46 in both embodiments establishes a first initial position, h_{1i} , of a column of blood (h_1) in one of the riser tubes (e.g., R1) and a second initial position, h_{2i} , of another column of blood (h_2) in the other of the riser tubes (e.g., R2). The valve mechanism 46 then isolates these columns of blood from the input circulating blood flow, resulting in the oppositely-moving columns of blood away from their initial positions as shown in Figs. 1A and 2A. Just prior to this isolation and during the movement of the columns of blood, each column of blood is monitored by a respective column level detector 54 and 56 which send their data to the microprocessor 58. As a result, the column level detectors 54/56 collect data ($h_1(t)$ and $h_2(t)$) regarding the movement

of these respective columns of blood, which can also be plotted (Fig. 10) and then displayed on the display screen 28.

It should be understood that it is within the broadest scope of the invention to replace one of the two column level detectors 54/56 with a single point detector in either of the two viscometers 20 and 120 (Figs. 1/1A and Figs. 2/2A) as disclosed in A.S.N. 09/573,267, filed on May 18, 2000, entitled DUAL RISER/SINGLE CAPILLARY VISCOMETER and whose entire disclosure is incorporated by reference herein. This modification is based on the symmetry of the column of blood height (i.e., $h_1(t)$ and $h_2(t)$) vs. time data (see Fig. 10). As long as one of the two columns of blood 82/84 is monitored, the height vs. time data for the other column of blood can be generated by using a single height point from that column. In the invention of the present application, it is only necessary to monitor the change in position of one of the columns of blood in either riser tube R1 or riser tube R2 and to detect only one point from the other column of blood. The preferred method/means is to monitor the rising column of blood 84 which occurs in riser tube R2 and to detect the initial viscosity test run level (i.e., h_{1i} , as discussed in A.S.N. 09/439,795) of the column of blood 82 in riser tube R1. Thus, it is within the broadest scope of this invention to cover a monitor that monitors either one of the moving columns of blood (which also includes methodologies known in the art such as monitoring the change in position, column height, weight, volume, mass, etc.) but not both columns (as is disclosed in A.S.N. 09/439,795) and a single point detector for detecting one point from the other moving column of blood.

Where both column level detectors 54/56 are used, or just one column level detector is used, a blood column movement indicator is also provided. This indicator provides either a visual and/or audible indication of the blood column movement. For example, as either

the falling column moves downward or the rising column moves upward, the indicator provides a flashing light whose flash rate is proportional to the speed of either the falling or rising column movement. Alternatively, or in addition, the indicator provides a continuous beeping sound whose beeping rate is proportional to the speed of either the falling or rising column. As a result, when the viscosity test run begins, and the falling and rising columns are moving at high rates, the indicator flashes and/or beeps at a high rate; near the end of the viscosity test run when the falling and rising columns are moving very slowly, the indicator flashes very slowly and/or beeps a slow rate. One example of the blood column movement indicator comprises including a sound card (e.g., Sound Blaster AWE64 manufactured by Creative) and speaker (not shown) in the display 28. As the columns of blood rise or fall, the processor 58 activates the speaker card which causes the speaker to emit a sound whose intensity varies with the speed of the blood column. In addition, the graphical depiction of the two height vs. time plots in the graphical display 61 can flash at a rate that varies with the speed of the column movement.

Based on the above discussion, the apparatus and method of the present invention are now discussed; the details of the other components in the blood receiving means 22/122 depicted in Figs. 1-2A are discussed in A.S.N. 09/439,795 and A.S.N. 09/501,856 and are not repeated here. Suffice it to say that using either one of the embodiments 20/120 the viscosity (μ) of the circulating blood of the living being can be determined as well as the absolute viscosity and effective viscosity profiles for that living being.

As shown in Figs. 1 and 2, several additional analyzers have been added in tandem with the circulating blood viscosity determination. These additional analysis means basically take advantage of the single intubation of the living being by the circulating blood conveying

means 26. In particular, a hematocrit analyzer 300, plasma viscosity analyzer 400, surface tension analyzer 500, and red blood cell deformability analyzer 600. The details of each of these will be discussed in below. Furthermore, to avoid overflowing these analyzers 300-600 with circulating blood, a valve 700 is used which permits a predetermined amount of blood to enter the respective analyzer and then closes off the path to these means.

Because the viscosity $\mu(t)$ of the circulating blood of the living being can be determined (as set forth in A.S.N. 09/439,795 and A.S.N. 09/501,856) as well as the absolute viscosity and effective viscosity profiles (as set forth in A.S.N. 09/501,856) for that living being, certain parameters of the heart can also now be determined: work of the heart (WOH) and contractility of the heart (CON).

WOH can be estimated from the following equation:

$$\text{Work of the Heart (WOH)} = \frac{1}{T} \int_0^T P(t) \cdot Q(t) dt$$

where:

P(t) is the pressure pulse curve of the heart (Fig. 3B);

Q(t) is the cardiac output (see Fig. 3A); and

T represents the period of one cardiac cycle.

In any flow system, the flow resistance comes from the piping arrangement and the type of fluids. As blood viscosity increases, the flow rate (i.e., cardiac output) decreases if the size of pump remains constant. In a steady state flow, the Poiseuille flow describes the flow rate (Q) in terms of the viscosity (μ) of the fluid, the length (L) of the tube, the inside diameter (d) of the tube and the pressure drop (ΔP) across the length of the tube, and is given as:

$$Q = \frac{\pi d^4 \Delta P}{128 \mu L} \quad (\text{Laminar flow})$$

The pumping power to generate Q can be given as pumping power = $Q \cdot \Delta P$.

For a pulsatile blood flow, the WOH is given as:

$$\frac{1}{T} \int_0^T P(t) \cdot Q(t) dt$$

where, for any given instantaneous flow,

$$Q(t) = \frac{\pi d^4 \Delta P(t)}{128 \mu L}$$

As used in the present context with regard to a living being's vascular system, the term $\Delta P(t)$ represents the pressure difference between the ends of a blood vessel of a fixed diameter and length. The vascular system between the heart (aorta) and vein is composed of blood vessels having different diameters and corresponding lengths which are known in the art. Since the pressure at the capillary bed can be approximated to be zero, the term, $\Delta P(t)$, can be approximated with the pressure pulse term, $P(t)$, such that the equation for WOH is defined as:

$$WOH = \frac{1}{T} \cdot \frac{\pi d^4}{128 L} \int_0^T P(t) \cdot \left[\frac{P(t)}{\mu(t)} \right] dt = \frac{\pi d^4}{128 T L} \int_0^T \frac{P^2(t)}{\mu(t)} dt$$

where “d” and “L” represent average diameter and length of the entire vascular system of a living being. The pressure pulse of the heart, P(t), can be detected by conventional medical equipment using, e.g., skin sensors and a digital storage oscilloscope. Thus, because the viscosity $\mu(t)$ of the circulating blood of a living being can be determined (Fig. 3C) using the viscometers 20/120, it is now possible to determine the WOH of the living being.

The contractility of the heart (COH) is the rate of ejection of blood by the left ventricle of the heart (Fig. 3D). The faster the heart squeezes blood out of the left ventricle, the greater is the contractility of the heart. In particular, as the contractility of the heart increases (from the dotted line 250 which indicates a first lower COH to the solid line 252 which indicates a second higher COH in the direction of the arrow 254), the pressure pulse wave becomes steeper during systole. Another term for COH is the “pulsatility” of the heart.

Quantitatively, the contractility can be measured from the pressure pulse curve (Fig. 3E). The slope of the pressure pulse curve in the beginning of systole represents how fast the left ventricle of the heart ejects blood. Hence, the slope represents the contractility of the heart. Mathematically,

$$\text{COH} = \text{slope} = \left(\frac{dp}{dt} \right)_{@t=0}$$

The importance of COH is discussed next with respect to blood viscosity and blood vessel wall shear stress.

Arterial disease often occurs at bifurcations (Fig. 4), but not in straight vessels. Hence, it is often called site-specific disease. In particular, it is known that blood flow recirculation occurs on the wall 256 opposite the flow divider 255 but has heretofore not been explained. One of the reasons may be hemodynamics.

5 In a bifurcation (Fig. 4), there is a flow 258 to the branch vessel 260. Thus, because the mass in the main vessel 262 decreases, the pressure at location LC2 increases compared to the pressure at location LC1, resulting in $P_{LC2} > P_{LC1}$, where "P" stands for pressure. This pressure differential forces some fluid elements to move upstream, producing a recirculation flow. A recirculation flow in an unsteady, pulsatile blood flow means that the wall shear stress between LC1 and LC2 is alternating between a negative value (e.g., - 5 dyne/cm²) and a positive value (i.e., +5 dyne/cm²). This same type of pressure differential also occurs at the proximal side 265 of the flow divider 255. In particular, a recirculation flow in an unsteady, pulsatile blood flow also occurs between location LC3 and location LC4 wherein $P_{LC4} > P_{LC3}$. This pressure differential forces some fluid elements to move upstream, producing a recirculation flow in the branch flow 258. This means that the wall shear stress between LC3 and LC4 is alternating between a negative value (e.g., - 5 dyne/cm²) and a positive value (i.e., +5 dyne/cm²). This alternating wall shear stress can be viewed as a sandpaper or abrading effect. The effect of this alternating shear on endothelial cells is very serious and the key to the arterial disease. In particular, endothelial cells 266 (Fig. 5B) become more rounded, forming dysfunctional endothelial cells which expose leaky sites, whereas normal, healthy endothelial cells 264 are elongated and contiguous (Fig. 5A).

As shown in Fig. 5B, endothelial cells (hereinafter, "E-cells") in a recirculating area become more rounded than elongated along the flow direction. Rounded E-cells are more permeable so that lipid and other macromolecules can move through the endothelial cell layer from blood to arterial wall 267 via the gaps, i.e., leaky sites 268. Hence, the E-cells do not perform their normal function and are called dysfunctional E-cells. When E-cells become rounded, the life of the cells become short, i.e., the cell turnover becomes high. When E-cells become dysfunctional, this causes a series of biological responses, including the production of nitric oxide (NO). In short, E-cells become dysfunctional due to oscillating/alternating wall shear stress in the low shear zones (1) at the wall 256 opposite the flow divider 255 and (2) at the proximal side 265 of the branch vessel 255.

By reducing the COH of the heart, one can reduce the magnitude of the oscillating wall shear stress in low-shear zones. It should be noted that it is not desirable to "reduce" low shear stress. What is desirable is to reduce the +/- swing. When a living being has a high contractility, the wall shear stress at the opposite wall 256 may vary from -10 to +10 dyne/cm². By administering a drug to reduce the contractility, one can correct the wall shear stress swinging from -3 to +3, wherein the E-cells will be much less dysfunctional. Thus, by reducing the contractility of the heart one can normalize the E-cell, reduce the number of dysfunctional E-cells, reduce cell turnover, reduce leaky sites, and reduce permeability of E-cells. The benefit of reducing contractility is to reduce the transport of lipids and other macromolecules across the E-cell layer, thus preventing the initiation and progression of arterial disease or atherosclerosis.

There are a number of drugs (such as beta-blockers) that can reduce the contractility of the heart. Smoking is known to increase the contractility of the heart, thus accelerating

the progress of atherosclerosis. Alcohol is well-known to relax the muscle of the left ventricle of the heart, thus decreasing the contractility of the heart. Caffeine (coffee) can increase the contractility of the heart. Thus, well-known risk factors, such as those addressed above, can be correlated to the contractility of the heart of a living being.

5 There is also a relationship between blood viscosity (μ) and dysfunctional E- cells. Blood viscosity affects the global hemodynamics at arterial vessels, particularly at arterial bifurcation 255, thus affecting E-cells. As blood viscosity increases, the flow separation zone increases and the magnitude of the alternating wall shear stress (i.e., the positive and negative values) is amplified. As blood viscosity decreases, the magnitude (or level) of the alternating wall shear stress decreases, resulting in more healthy E-cells, i.e., less dysfunctional E-cells. The shape of the E-cells is less round and the E-cell turnover decreases. Hence, the reduced blood viscosity can reduce the transport of lipids and macromolecules across the E-cell layer (i.e., intima). Therefore, any drugs reducing blood viscosity can reduce the number of dysfunctional E-cells which are often called intimal injury at the early stage of atherosclerosis.

10
15
20 Reduced viscosity can reduce the permeability of leaky junctions, thus reducing intimal injury. It should be noted that enhanced permeability of E-cells causes influx of lipids and macromolecules. Reduced viscosity does reduce the magnitude of high shear stress at the flow divider 255 of an arterial bifurcation because wall shear stress is proportional to blood viscosity.

 There is also a relationship between blood viscosity and thrombosis. Thrombosis often occurs in the later stages of the arterial disease. Blood viscosity may be indirectly related to thrombogenesis. By reducing blood viscosity, the occurrence of thrombosis can

be reduced because reduced blood viscosity increases flow velocity. Coagulability or thrombogenicity of blood indicates the blood's tendency to coagulate, form thrombi, aggregate platelets or clot. Thus, as shown in Fig. 11, by measuring both the absolute and effective blood viscosity profiles and monitoring the angle between the two profiles, θ , one can quantitatively evaluate the blood's tendency to form thrombi, as discussed in A.S.N. 09/501,856.

As mentioned earlier and as shown in Figs. 1 and 2, four additional analyzers have been introduced, namely, hematocrit analyzer 300, plasma viscosity analyzer 400, surface tension analyzer 500 and red blood cell deformability analyzer 600. Each of these analyzers operate independently of the blood viscometers 20/120 but take advantage of sharing the single intubation of the living being via circulating blood conveying means 26.

With regard to the hematocrit analyzer 300 (Figs. 6-8), there is a need to monitor the level (percentage) of hematocrit of blood on a real time base. As blood is drawn out of a living being, if one can measure or monitor the hematocrit, it can improve health care quality, diagnostic capability and treatment.

Currently, hematocrit (which is defined as the volume percentage of red blood cells in whole blood wherein the hematocrit of a normal healthy individual is approximately 40% - 45%) is measured using a small capillary tube where a small amount of blood is filled from one end, and the end is closed by an amorphous, dough-like material. Using a (micro) centrifuge, cells from blood are separated from plasma and the volume of the cells is read in terms of percentage, called hematocrit.

In contrast, the present invention implements a hematocrit analyzer 300 which utilizes an optical non-contact method. Blood is diverted from the circulating blood conveying

means 26, through the valve 700 and into the hematocrit analyzer 300. In particular, the blood sample flows through a transparent capillary tube 302 of approximately 20-50 μ m ID. A pulsing light 304 (e.g., a strobe light) provides illumination and optically “freezes” the motion of cells inside the tube 302. A red blood cell detector 305 is used to count the red blood cells and may comprise a CCD camera microscope 306 and an image processing means 308. Multiple imaging frames, e.g., 10 frames/second, can be captured by the CCD (charge coupled device) camera/microscope 306 (e.g., a CCD having 300 dpi- 83 μ pixel resolution available from ScanVision Inc. of San Jose, CA) and processed through the image processor 308 which includes image processing software (e.g., conventional CCD acquisition software available with the ScanVision Inc. CCD mentioned previously). The image processor 308 identifies cells and counts the number of cells in a given window 310 (Fig. 7). The given window has a predetermined volume. Since one can calculate the total volume and cells from cell count, one can estimate the volume percentage of cells, thus hematocrit. The total volume and cell count can then be transmitted to a computer 312, or to the microprocessor 58 (Figs. 1 and 2) in the viscometer 20/120.

The new method utilized by the hematocrit analyzer 300 can easily be validated by comparing the hematocrit data generated from the analyzer 300 with those obtained from the conventional method such as the microcentrifuge method described earlier.

Fig. 8 depicts an alternative lumen to the capillary tube 302. In particular, a rectangular glass tube or lumen 314, which is readily available off-the-shelf, can be used and a predetermined window 316 can be established for conducting the total volume and cell count.

10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

Figs. 9A-9C depict portions of the plasma viscosity analyzer 400 which basically comprises a first vacutainer 402, an optional high pressure source 404, a second vacutainer 406 and an automated volume reader 408. Unlike the conventional way plasma is obtained, e.g., utilizing a centrifuged blood sample, in the plasma viscosity analyzer 400, a portion of the circulating blood is diverted therein from the living being using the single intubation of the living being via the circulating blood conveying means 26. In particular, as can be seen from Fig. 9A circulating blood is diverted to the plasma viscosity analyzer 400 via the valve 700. A lumen 410 (e.g., a 21 gauge needle) releasably fits into the valve 700. The other end of the lumen 410 passes through a rubber membrane or plug 412 in the top portion of a first vacutainer 402. Disposed inside at the center of the vacutainer 402 is a porous medium, e.g., a membrane filter 414, which separates the vacutainer 402 into an upper chamber 416 for collecting the circulating blood 15 therein and a lower chamber 418 that initially comprises a vacuum.

The membrane filter 414 separates cells only, but not fibrinogen. A filter membrane used for ultra-filtration with a pore size of approximately $0.1\mu\text{m}$ should be suitable for this purpose.

Once the circulating blood conveying means 26 is in fluid communication with the plasma viscosity analyzer 400 via valve 700, blood 15 flows into the upper chamber 416. Under the influence of gravity and the pressure differential, the red blood cells are separated from the plasma 17 (Fig. 9B) via the membrane filter 414, i.e., the red blood cells remain in the upper chamber 416, with the plasma 17 being collected in the lower chamber 418.

Furthermore, if the vacuum in the lower chamber 418 is not sufficient to pull plasma through the membrane 414, to accelerate this separation process, the first vacutainer 402

can be disengaged from the valve 700 and coupled to a high pressure source 404 (Fig. 9B, e.g., compressed air). The high pressure source 404 forces the collected blood 15 against the porous membrane 414 and thereby separates the plasma 17 much more quickly. It is important to note that plasma 17 is a Newtonian fluid, therefore the viscosity thereof does not vary with shear rate. Thus, to determine the plasma viscosity, it is only necessary to obtain one shear rate, i.e., it is not necessary to monitor the change in height of a column of plasma.

As shown in Fig. 9C, once the red blood cells and plasma are separated, the first vacutainer 402 is disengaged from the valve 700 (or from the high pressure source 404, if used). A second vacutainer 404, having graduations indicating different volume levels, is coupled to the first vacutainer 402. In particular, a lower rubber membrane or plug 420 of the first vacutainer 402 is pierced by another lumen 422 (e.g., a 21 gauge needle). The other end of the lumen 422 is disposed through a rubber membrane plug 424 of the second vacutainer 404. With the first lumen 410 is exposed to atmosphere (i.e., zero gauge pressure) as shown in Fig. 9C, the pressure above the plasma 17 is atmospheric pressure; furthermore, the second vacutainer 404 comprises a predetermined vacuum level. Because of this pressure differential (Δp) between the two vacutainers 402/404, when the second lumen 422 punctures the membrane/plug 420, the plasma 17 is forced down out of the first vacutainer 402 down into the second vacutainer 404 via the lumen 422.

As mentioned earlier, since plasma is a Newtonian fluid, plasma viscosity can be determined from a single shear rate, according to the equation:

$$Q = \frac{\pi d^4 \Delta P}{128 \mu_p L}$$

where

L = second lumen 422 length;

d = second lumen 422 inside diameter;

ΔP = pressure difference between the two vacutainers 402/404 as shown in Fig. 9C (i.e, pressure levels are predetermined and vary depending on the accumulated plasma amount, thus mathematically estimated, no need to measure)

Q = flow rate, or volume/time; and

μ_p = plasma viscosity.

Thus, μ_p , is given by $\mu_p = \frac{\pi d^4 \Delta P}{128 Q L}$.

By measuring the volume of plasma 17 accumulated over a given period (e.g., 1 minute) in the second vacutainer 406 using the predetermined/premarked lines 426 on the side wall of the vacutainer 406 using a manual method or an automated volume reader 408, the plasma viscosity can be calculated. Alternatively, one can measure the mass of the second vacutainer 406 over a given period (e.g., 1 minute) from which one can estimate the plasma viscosity.

In another aspect of this invention, it is desirable to utilize blood pressure, the heart's pressure pulse curve, and blood viscosity information in order to estimate wall shear stress in high and low shear areas of a (coronary) bifurcation. As discussed earlier with regard to Fig. 4, the circulating blood flows at the (1) wall 256 opposite the flow divider 255 and at the (2) proximal side 265 of the branch vessel 255 are experiencing low wall shear stress whereas the distal side 269 of the branch vessel 255 is experiencing high shear wall stress.

In particular, the inventors have developed a table (Fig. 13) showing both high and low wall shear stress that is based on computational fluid dynamic (CFD) modeling of the coronary bifurcation flow. Two parameters are used, namely BPN (i.e., blood pressure number) and BVP (blood viscosity parameter), which will be defined later below.

5 To use the wall-shear-stress table, it should be understood that it is practically impossible to calculate oscillating wall shear stress based on BPN and BVP data on a real time basis with current high speed computers. Furthermore, it may not be necessary to have complicated pulsatile flow information for ordinary clinical diagnostics and treatments of various diseases such as hypertension, diabetes, etc.

10 The table (Fig. 13) provides the high and low shear data as soon as the BPN and BVP data become available. For example, if a patient has a BVP III level and BPN5 level, one can read from the table the corresponding values of high wall shear stress (high τ_w) and low wall shear stress (low τ_w). The objective of any drug administration and clinical treatment is to move a patient condition from the lower right corner (i.e., the worst wall shear stress conditions) to the upper left corner (i.e., the ideal wall shear stress conditions).

15 The definitions of BVP and BPN are discussed next. To understand the definition of BVP, it is necessary to discuss the absolute viscosity profile and the effective viscosity profile in view of Figs. 10-12B. As disclosed in A.S.N. 09/501,856, once the height vs. time data is collected from changing column levels in the riser tubes R1 and R2, that data can be segmented into a first shear rate range A (e.g., 320s^{-1} to 1s^{-1}) and a second shear rate range B (e.g., 1s^{-1} to 0.02s^{-1}). It should be understood that the particular shear rate selected to define the end of range A and the beginning of range B, e.g., 1s^{-1} , is by way of example

only and not limitation; thus, it is within the broadest scope of this invention to cover any number of shear rates that define the end of range A and the beginning of range B.

When the blood viscosity is plotted over time in a log-log scale, the viscosity profile over the first shear rate range (A) is called the “absolute viscosity profile” and the viscosity profile over the first and second shear rate ranges (A+B) is called the “effective viscosity profile” (see Fig. 11). As also disclosed in A.S.N. 09/501,856, the angle θ (Fig. 12A) formed between the absolute viscosity profile and the effective viscosity profile can be used as an indicator of blood parameters. As is also discussed in A.S.N. 09/501,856, it is desirable to minimize the angle θ as shown in Fig. 12B by providing medications, changing the living being's lifestyle, or both, etc.

The blood viscosity parameter (BVP) is a value that is determined from comparing the effective viscosity profile 800 of the living being under test (UT) to the effective viscosity profile 802 of a normal healthy living being, e.g., a healthy young boy, as shown in Fig. 12C. For a normal healthy person, BVP varies between approximately 5 -10 and is defined as:

$$BVP = \left(\frac{\mu_{effective}}{\mu_{absolute}} - 1 \right) \cdot 50 + \left(\frac{\mu_{150}}{4} \right) \cdot 2 + \left(\frac{\mu_1}{8} \right) \cdot 3$$

where:

- $\mu_{effective}$ is the the effective viscosity profile 800 of a living being UT;
- $\mu_{absolute}$ is the absolute viscosity profile and the effective viscosity profile 802 of a normal healthy person, in a log-log graph;
- μ_{150} is the living being UT's circulating blood viscosity measured at $\dot{\gamma} = 150 \text{ s}^{-1}$; and
- μ_1 is the living being UT's circulating blood viscosity measured at $\dot{\gamma} = 1 \text{ s}^{-1}$.

The first term $\left(\frac{\mu_{effective}}{\mu_{absolute}} - 1 \right) \cdot 50$ is known as the “effective/absolute viscosity” term

and represents blood's thrombotic tendency. The second term $\left(\frac{\mu_{150}}{4} \right) \cdot 2$ is known as the

“high shear effect” term and the third term $\left(\frac{\mu_1}{8} \right) \cdot 3$ is known as the “low shear effect” term.

The denominators of the high shear effect term and the low shear effect term are used as references and are the viscosity values (4 and 8 centipoise) from a healthy young boy at the shear rates of 150 s^{-1} and 1 s^{-1} , respectively (see Fig. 12C). For diabetes, the high shear effect term can be much greater. A weighting factor of “3” is used with the low shear effect term because the low shear viscosity is often a direct cause of arterial disease. Furthermore, since μ_1 for the subject is often much greater than 8 centipoise for most adults, the low shear effect term can be the largest contributor among the three terms. A weighting factor of “2” is used with the high shear effect term since the effect of high shear on atherosclerosis is less than that of low shear viscosity.

With regard to the BPN, the BPN can be defined as an average blood pressure term (i.e., the average value of the systole and diastole) and a contractility of the heart (COH) term.

Once a BVP and a BPN is determined for any particular living being, these values can be immediately referenced according to the table shown in Fig. 13 and the high and low wall shear stress indicated. Depending on the patient's particular BVP/BPN, the physician and/or specialist can then devise a regimen of drugs and/or lifestyle changes (as mentioned previously) to move the patient's cardiovascular system toward the upper left corner of the table in Fig. 13.

As mentioned earlier, the $h_1(t)$ and $h_2(t)$ data/curves of the viscometers 20/120 can be segmented into two shear rate regions (A and B) and from which an absolute viscosity profile and an effective viscosity profile can be obtained. These $h_1(t)$ and $h_2(t)$ data/curves can be further segmented into a plurality of regions (see Fig. 17), resulting in a plurality of viscosity profiles (see Fig. 18A), and two of which are the absolute viscosity profile (III, in Figs. 12A and 18A) and the effective viscosity profile (VI, in Figs. 12A and 18A). As an example, as shown in Fig. 17, the $h_1(t)$ and $h_2(t)$ data/curves have been segmented into six regions.

The determination of the blood viscosity profile for each segment is in accordance with the equations set forth in A.S.N. 09/501,856 and A.S.N. 09/439,795 but wherein the data used for each region is defined as follows:

Region I: $0 < t < t_1$
Region II: $0 < t < t_2$
Region III: $0 < t < t_3$
Region IV: $0 < t < t_4$
Region V: $0 < t < t_5$
Region VI: $0 < t < t_6$,

i.e., for each new region analyzed, all prior height vs. time data is used. It should be noted that in the first region, Region I, the blood viscosity calculated using the data $0 < t < t_1$ is a

freshly shed, high shear blood viscosity. It is also desirable to obtain viscosity data in a shear rate range $> 100 \text{ s}^{-1}$. It should also be noted that the blood viscosity calculated using Region VI data contains the most significant effect of coagulation/clotting because while the columns of blood in riser tubes R1 and R2 fall and rise, respectively, the blood is exposed to air. Thus, the $h_1(t)$ and $h_2(t)$ data/curves contain information about the blood's coagulability characteristics. This segmentation of these data/curves and the subsequent analysis helps further define these coagulability characteristics of the blood.

Based on the above, Figs. 18A and 18B provide the various blood viscosity profiles (in a log viscosity vs. log shear rate plot) over the six regions, for two hypothetical patients: patient A (Fig. 18A) and patient B (Fig. 18B). By examining the spread in the blood viscosity profiles, one can make a judgment in terms of diagnostics and treatment. For example, patient A shows almost Newtonian type high shear viscosity (Region I viscosity profile is substantially horizontal, i.e., the viscosity in that region does not vary over shear rate). Thus, since it is now possible to identify the blood viscosity profile in the high shear rate range, it is possible to develop and test drugs that alter the living being's blood viscosity to achieve such Newtonian-like performance at high shear rates.

Fig. 19 confirms that the plurality of blood profiles depicted in Figs. 18A and 18B form the central portion of the log viscosity vs. log shear rate plots, i.e., the extreme ends, both extreme high shear rates and extreme low shear rates, are not plotted or used.

The surface tension analyzer 500 (Figs. 16A-16B) provides a measurement of the surface tension of a liquid; in the preferred embodiment blood is the liquid whose surface tension is being determined. Typically, surface tension is measured using a bubble-blowing method; however, this method is labor-intensive and a time-consuming procedure. When

liquid becomes hazardous to handle, e.g., human blood, it is desirable to have a fully automated procedure.

In general, where the surface tension of a liquid is being determined using a cylindrical capillary tube, the surface tension is defined as that upward vertical force which balances the weight of the liquid element. In most liquid/solid interfaces, a contact angle, δ , is formed between the liquid and the capillary tube, such as that depicted in Fig. 14A. However, where the liquid whose surface tension is being determined is water or blood, the contact angle $\delta = 0^\circ$ and therefore the vertical component of surface tension, namely, $\pi d \sigma \cos \delta$ which counteracts the weight of the liquid, is simply $\pi d \sigma$. Thus, the surface tension, σ , is calculated based on the following:

$$\pi d \sigma = \rho \left(\frac{\pi d^2}{4} h \right) g,$$
$$\sigma = \frac{\rho d h g}{4}$$

where

σ = surface tension (N/m)

d = capillary tube inside diameter (m); and

h = the height of the liquid element (m)

The surface tension analyzer 500 provides a unique manner for accurately determining the height of the liquid element in the surface tension analysis using capillary rise, as is discussed below.

As shown in Fig. 16A, the surface tension analyzer 500 comprises a conduit 502 from the valve 700, a stopcock 504, a capillary tube 506, a CCD sensor array 508, an elbow 509, a mini-reservoir 510 and an adjacent overflow chamber 512. An aperture 514 is provided in one of the walls of the mini-reservoir 510 adjacent the overflow chamber 512. As will be discussed below, as the column of blood 513 flows down the capillary tube 506, through the stopcock 504, through the elbow 509 and into the mini-reservoir 510, the aperture 514 controls the blood level 516 in the mini-reservoir 510, i.e., as the collected blood level 516 rises to or above the aperture 514, blood flows into the overflow chamber 512. As a result, the exact level of blood in the mini-reservoir 510 is maintained. The CCD sensor array 508 is positioned at a predetermined height, h_r , above the aperture 514. As is discussed below, when the CCD sensor array 508 detects the final position of the column in the capillary tube 506, the predetermined height, h_r , can be programmed into the CCD sensor array 508 as an offset such the height necessary for the surface tension calculation, namely, h_r , is sent to the processor 58. In the alternative, the predetermined height, h_r , can already be stored in the processor 58 and only the final position of the column in the capillary tube 508 is detected and transmitted by the CCD sensor array 508 to the processor 58; the processor 58 then adds the value h_r to the final position of the column height to arrive at h_r . In either case, the processor 58 calculates the surface tension according to the above equation.

The surface tension analyzer 500 operates as follows: Before the test is run, the inside of the capillary tube 506 is wetted by the blood of the living being as it flows from the

valve 700. In particular, with the stopcock valve 504 in its initial position as shown in Fig. 16A, the blood flows upward into the capillary tube 506, whose top (not shown) is vented to atmosphere. When the CCD sensor array 508 detects a predetermined level (not shown) of the column of blood 513 in the capillary tube 506, the stopcock valve 504 is rotated to isolate the capillary tube 506 from the conduit 502 and to couple the tube 506 to the elbow 509 and mini-reservoir 510. As the stopcock valve 504 connects the capillary tube 506 to the mini-reservoir 510, blood in the capillary tube 506 falls and settles at a level, h_f . The CCD sensor 508 monitors the final position of the column 513. It should be noted that h_f is the distance between the blood level in the capillary tube 506 and the level 516 in the mini-reservoir 510 and therefore represents the height of the liquid element required for determining the surface tension, σ , as discussed above. The aperture 514 on the side wall of the mini-reservoir 510 controls the blood level 516 in the reservoir 510. Blood from the reservoir 510 flows into the overflow chamber 512 if the fluid level 516 rises above the aperture 514. Using this level-control aperture, the exact level of blood 516 in the mini-reservoir 510 is known.

Because surface tension, σ , is related to yield stress, τ_0 , (as discussed in A.S.N. 09/501,856) which is related to RBC (red blood cell) agglomeration (see Fig. 22 where at high shear conditions, the blood cells bonds are evenly spaced allowing these bonds to be easily severed versus low shear conditions where the cells are closely stacked, known as a Rouleaux formation, and where the yield stress/RBC agglomeration causes thrombosis), using the surface tension analyzer 500, it is now possible to determine whether a drug reduces or increases the surface tension of whole blood. In particular, Fig. 21 depicts a

method for treating low shear injury through the use of surface tension analyzer 500. The determination of the surface tension of blood can be of great assistance to pharmaceutical companies in their quest to manufacture drugs that reduce the surface tension of whole blood. One of the benefits of reducing the surface tension of blood is to reduce blood viscosity and the work of the heart. For example, saline IV solution and distilled water reduces surface tension and blood viscosity, thus reducing the work of the heart. In addition, blood letting can reduce the surface tension.

Another use of blood viscosity measurement is for treatment of patients with peripheral arterial disease (PAD). Patients with PAD often experience claudication (i.e., lower extremity pain, ache or cramp in the calf, buttock or thigh). PAD occurs when fatty deposits buildup in the arteries, decreasing blood supply to the part of the upper or lower body. This could be due to the insufficient blood flow to the lower extremities. Hence, drugs to reduce peripheral vascular resistance (PVR) are often administered to improve blood flow, thereby reducing pain/ache caused by PAD.

As shown in Fig. 20, a method can be used to improve blood perfusion to the lower extremities by reducing blood viscosity. As mentioned earlier, the reduction of blood viscosity can be accomplished by blood letting or the injection of distilled water (i.e., saline IV solution) or mechanical vibration. By improving circulation and reducing PVR, one can reduce pain while increasing walking distance, as well as quality of life in individuals with intermittent claudication.

Another use of the above methods and apparatus is in the control of hypertension. Typically, there are four basic approaches to control hypertension, each of which is administered independent of the other:

1) β -blocker/calcium-channel blocker which slows down the heart, thereby reducing COH;

2) ACE inhibitor - vasodilator (which opens capillaries in upper/lower extremities);
- pure blood pressure lowering drugs;

3) Blood viscosity reduction

- blood thinner like Coumadin
- Fish oil
- Blood letting
- Cholesterol-lowering drugs

4) Diuretics - removes water from blood - but actually increases blood viscosity.

In light of the above, a new method of treating hypertension is to apply β -blocker/calcium-channel blocker, ACE inhibitor (including the vasodilator and blood pressure lowering drugs) and blood viscosity reducing drugs in combination to effectively reduce hypertension. The use of diuretics is not to be used with this combination since it has just the opposite effect. The combined use of these three can reduce the work of the heart, and the overall risk of the vascular disease.

Fig. 15 depicts the red blood cell deformability analyzer 600. In particular, the analyzer 600 comprises a plurality of tubes 602 having various inner diameters in the range from 1 μ m to 10 μ m and with each tube 602 being in contact with its neighboring tube 602. When circulating blood enters the analyzer 600 from the valve 700, depending on the size of a particular red blood cell (RBC), each RBC will either (1) enter that tube 602 which is large enough for the RBC to pass through, or (2) enter that tube 602 for which the RBC is able to deform without rupturing. As the RBCs collect in various tubes 602, a light source 604 illuminates the plurality of tubes 602. The light passing through the tubes 602 having varying degrees of "redness" is detected by a red color detector 606 (e.g., light source

604/color detector 606 can be implemented by the CS64A color sensor manufactured by Delta Computer Systems, Inc. of Vancouver, WA which comprises both a light generation system and a light receiving system for detecting color; a digital/analog converter is used to make the output of the CS64A compatible for computer processing). The higher degree of redness, the higher the RBC content in the tube 602. The red color detector 606 collects the redness information along with the corresponding tube 602 and then passes this information to the processor 58.

Figs. 14A-14B depict another blood characteristic detector: a blood lubricity detector 800.

It should be understood that although the term "lubricity" is known by those skilled in the mechanical arts as describing the slipperiness between two solids, the term "lubricity" as used in this patent application refers to the "slipperiness" of the blood flow with respect to the vessel wall, i.e., the slipperiness between a liquid (blood) and a solid (the vessel wall).

Furthermore, it should also be understood that another parameter of the blood is the blood's "adhesiveness" which refers to the property of the blood which causes it to cling to the vessel walls. The lubricity and the adhesiveness of the blood are inversely related, namely, as adhesiveness increases the lubricity decreases, and vice versa.

In particular, as shown in Fig. 14A, a meniscus 802 forms at the top of the column of blood as it falls down the riser tube R1. As the meniscus 802 falls, a thin residue of blood of varying thickness is left on the inside surface of the riser tube R1; this is indicated by the reference numbers 804A and 804B. As can be seen, the residue has a minimum thickness at the higher elevations 806 of the riser tube R1 and maximum thickness closest to the

meniscus 802 itself, as indicated by the reference number 808. The amount of this residue is indicative of the lubricity of the blood and is exemplary of the lubricity of the blood as it travels through the vascular system of a living being.

To measure this varying amount of film, the lubricity detector 800 is used. The detector 800 comprises a light source 810 located on one side of the riser tube R1 near its top portion. The detector 800 also comprises a light detector 812 located on the opposite side of the top portion of the riser tube R1, directly opposite the light source 810. Depending on the thickness of the thin film layer, light rays 814 emanating from the light source will pass through the riser tube R1 wall, a portion of the film of blood on one side of the tube R1, the other thin layer of blood on the opposite side of the tube R1 and through the other side of the riser tube R1 to be detected by the light detector 812. As the residue gets thicker, eventually the light rays 814 directed at that portion of the residue cannot pass through and, as result, are not detected by the detector 812.

An example of the light detector 812 is a CCD having a vertical array of pixels (or an active-pixel sensor (APS) comprising rows/columns of pixels). Light rays 814 that pass through the blood residue in the riser tube R1 impact the pixels at a certain illumination level for different height levels (x) depending on the thickness of the blood residue. If a Gray scale is used to designate varying degrees of illumination (e.g., 256 = full light intensity detected; 0 = no light detected at all) such pixel data is transmitted to the processor 58 which plots all of these Gray scale values as a function of the vertical position, x. Fig. 14C depicts such plots for different living beings. The processor 58 determines the slope of each curve which is an indicator of the lubricity of a particular living being's blood. An alternative indicator of lubricity may comprise the sum of Gray scale values over a specified vertical

length; the higher the sum value, the greater the lubricity since there is little or no blood residue blocking the light rays 814. In a normal healthy living being the lubricity should be high so that a minimum amount of residue, having a minimum thickness, would be left on the inside of the riser tube R1.

5 It should be understood that blood pressure monitors such as the implantable blood pressure monitors disclosed in U.S. Patent No. 6,015,386 (Kensey, et al.), whose entire disclosure is incorporated by reference herein, or any other type of blood pressure monitor, can be used in combination with the viscometers 20/120 as shown in Figs. 1 and 2 to accomplish the methods described herein. For example, the implantable blood pressure monitors of U.S. Patent No. 6,015,386 (Kensey, et al.) can be implanted in the living UT and can be used in determining the COH and/or generating the BPN, both of which are discussed above.

The above-described apparatuses and diagnostic methods enable the practice of a variety of prophylactic and/or therapeutic methods using a variety of prophylactic and/or therapeutic compositions to control at least one property of blood measured by the apparatus and methods of the invention.

Without further elaboration, the foregoing will so fully illustrate our invention and others may, by applying current or future knowledge, readily adapt the same for use under various conditions of service.

CLAIMS

We claim:

1. A method for determining the work of the heart of a living being, said method comprising determining the viscosity of the blood circulating within the living being.

2. The method of Claim 1 wherein said method comprises the steps of:

(a) measuring the viscosity of the circulating blood of the living being over a plurality of shear rates;

(b) detecting a pressure pulse of the heart of the living being; and

(c) determining the work of the heart from a combination of said viscosity of the circulating blood of, and the pressure pulse of the heart of, the living being.

3. The method of Claim 2 wherein said step of determining the work of the heart (WOH) is defined as:

$$WOH = \frac{\pi d^4}{128TL} \int_0^T \frac{P^2(t)}{\mu(t)} dt$$

where:

T is a period of one cardiac cycle;

P(t) is the pressure pulse of the heart;

d represents the average inside diameter of the entire vascular system from the heart to the vein;

L represents the average length of blood vessels from the heart to vein; and

$\mu(t)$ is said viscosity of the circulating blood over a plurality of shear rates.

4. A method for determining the rate of ejection of blood from the heart of a living being, said method comprising detecting a pressure pulse of the heart.

5. The method of Claim 4 wherein said method of determining the rate of ejection of the blood from the heart further comprises the step of determining the rate of change over time of said pressure pulse of the heart at the beginning of the pressure pulse.

6. A method for reducing endothelial cell dysfunction in a living being which is caused by oscillating flow of the circulating blood of the living being, said method comprising the step of reducing the rate of ejection of the blood from the heart of the living being.

7. The method of Claim 6 wherein said step of reducing the rate of ejection of the blood from the heart comprises administering a β -blocker to the living being.

8. The method of Claim 6 wherein said step of reducing the rate of ejection of the blood from the heart comprises minimizing or eliminating smoking by the living being.

9. The method of Claim 6 wherein said step of reducing the rate of ejection of the blood from the heart comprises minimizing or eliminating the ingestion of caffeine by the living being.

10. The method of Claim 6 wherein said step of reducing the rate of ejection of the blood from the heart comprises ingesting of alcohol by the living being.

11. A method for reducing endothelial cell dysfunction in a living being which is caused by oscillating flow of the circulating blood of the living being, said method comprising the step of reducing the viscosity of the circulating blood of the living being.

12. The method of Claim 11 wherein said step of reducing the viscosity of the circulating blood of the living being comprises administering blood viscosity reducing drugs to the living being.

13. The method of Claim 12 wherein said blood viscosity reducing drugs comprises cholesterol lowering drugs.

14. The method of Claim 11 wherein said step of reducing the viscosity of the circulating blood of the living being comprises administering fish oil to the living being.

15. The method of Claim 11 wherein said step of reducing the viscosity of the circulating blood of the living being comprises performing blood letting on the living being.

5 16. A method for reducing endothelial cell dysfunction in a living being which is caused by oscillating flow of the circulating blood of the living being, said method comprising the steps of reducing the rate of ejection of the blood from the heart of the living being and reducing the viscosity of the circulating blood of the living being.

17. A method for determining a hematocrit of blood circulating within a living being, said method comprising optically counting red blood cells in a known volume of the circulating blood where red blood cells and plasma have not been artificially separated.

18. The method of Claim 17 wherein said optically counting comprises:

(a) diverting the circulating blood through a transparent conduit of known dimensions; and

(b) analyzing an image of said diverted circulating blood through said transparent conduit to count the number of red blood cells in said diverted circulating blood.

19. An apparatus for determining the hematocrit of the circulating blood of a living being without having to separate red blood cells from the plasma of the circulating blood, said apparatus comprising an optical analyzer.

20. The apparatus of Claim 19 wherein said optical analyzer comprises:

a transparent conduit for conveying the circulating blood therethrough;

a light source for illuminating a predetermined portion of said conduit;
and

red blood cell detector for counting the number of red blood cells
passing through said illuminated predetermined portion of said conduit.

5 21. The apparatus of Claim 20 wherein said red blood cell detector comprises a
charge coupled device and associated image processing software.

22. A method for determining a plasma viscosity of the circulating blood of a living
being, said method comprising analyzing a single shear rate of flowing plasma, said plasma
comprising a non-centrifuged sample of the circulating blood.

23. The method of Claim 22 wherein said analyzing comprises:

(a) providing a plasma sample in a first container at a first pressure
level;

(b) providing a second container having a known initial internal
pressure level lower than the first pressure level;

(c) establishing fluid communication between said first container and
said second container via a lumen having known dimensions;

(d) detecting a rate of plasma volume change in said second container
when said fluid communication is established; and

(e) determining the plasma viscosity from the rate of plasma volume
change, the known dimensions of the lumen and a difference between the first
pressure level and the initial internal pressure.

24. An apparatus for determining the viscosity of the plasma of the circulating blood of a living being without the need to centrifuge a portion of the circulating blood of the living being and utilizing single shear rate analyzer.

25. The apparatus of Claim 24 wherein said single shear rate analyzer comprises:

5 a first vacutainer for creating a plasma sample from the portion of the circulating blood and storing it at a known first pressure level;

a lumen having known dimensions;

a second vacutainer having a known initial internal pressure level lower than said first pressure level;

10 a detector for detecting the rate of volume change in said second vacutainer when said lumen is coupled between said first vacutainer and said second vacutainer; and

15 a calculator for determining the viscosity of the plasma from said rate of volume change, said known dimensions of said lumen and the difference of said first pressure level and said initial internal pressure.

20 26. The apparatus of Claim 25 wherein said first vacutainer comprises a porous medium therein that separates said first vacutainer into a first chamber and a second chamber, said first chamber for receiving a portion of the circulating blood of the living being therein and said porous medium retaining the red blood cells within said first chamber while permitting the plasma in said portion of the circulating blood to pass through into said second chamber.

27. The apparatus of Claim 25 wherein said calculator determines the plasma viscosity, μ_p , utilizing the following equation:

$$\mu_p = \frac{\pi d^4 \Delta P}{128 Q L},$$

where:

- 5 d is the inner diameter of said lumen;
 L is the length of said lumen
 Q is said rate of volume change; and
 Δp is said difference of said first pressure level and said initial internal pressure.

10 28. A method for estimating blood vessel wall shear stress in high and low shear areas of a blood vessel bifurcation of a living being by correlating a blood viscosity parameter with a blood pressure parameter.

15 29. The method of Claim 28 wherein said step of correlating a blood viscosity parameter with a blood pressure parameter comprises the steps of:

 (a) determining a first viscosity profile of the circulating blood of the living being over a plurality of shear rates and a second viscosity profile of the circulating blood of a healthy living being over said plurality of shear rates for use as a reference;

 (b) defining a blood viscosity parameter that comprises:

20 (1) a high shear rate blood viscosity component based on high shear rate blood viscosity values from said first and second viscosity profiles;

(2) a low shear blood viscosity component based on low shear rate blood viscosity values from said first and second viscosity profiles; and

(3) a component representing the thrombotic tendency of the blood;

(c) defining a blood pressure parameter that comprises:

(1) an average blood pressure term; and

(2) a rate of ejection of blood from the heart of the living being; and

(d) providing a matrix having a plurality of said blood viscosity parameters along a first axis of said matrix and a plurality of said blood pressure parameters along a second orthogonal axis and wherein the intersection of any one of said plurality of said blood viscosity parameters and any one of said plurality of said blood pressure parameters specifies a particular high wall shear stress and low wall shear stress.

30. The method of Claim 29 wherein said high shear rate blood viscosity component comprises a ratio of a blood viscosity value from said first viscosity profile at a high shear rate to a blood viscosity value from said second viscosity profile at said high shear rate.

31. The method of Claim 29 wherein said low shear rate blood viscosity component comprises a ratio of a blood viscosity value from said first viscosity profile at a low shear rate to a blood viscosity value from said second viscosity profile at said low shear rate.

32. The method of Claim 29 wherein said component representing the thrombotic tendency of the blood comprises a ratio between an angle formed between said first and second viscosity profiles to a predetermined value.

33. A method for analyzing the viscosity of the circulating blood of a living being, said method comprising the steps of:

(a) determining viscosity data of the living being's circulating blood for a plurality of shear rates over a test run time;

(b) segmenting said test run time into a plurality of time segments; and

(c) generating a blood viscosity profile for each of said time segments from the beginning of said test run until the end of each of said time segments.

34. The method of Claim 33 further comprising the steps:

(a) plotting each of said blood viscosity profiles on a common log viscosity vs. log shear rate graph; and

(b) utilizing the spatial relationships between each of said blood viscosity profiles for diagnostics and treatment of the living being.

35. The method of Claim 34 further comprising the steps of developing and testing drugs that alter the living being's blood viscosity to achieve Newtonian type performance at high shear rates.

36. The method of Claim 34 further comprising the step of obtaining coagulation and clotting information from blood viscosity profiles.

37. An apparatus for automatically determining the surface tension of the circulating blood of a living being, said apparatus comprising a blood column height determinator based on capillary rise.

38. The apparatus of Claim 37 wherein said column height determinator comprises:

5 a lumen having a first end vented to atmosphere and a second end coupled to one port of a valve, said valve having a second port coupled to a source of circulating blood of the living being;

 a reservoir, vented to atmosphere, having an input coupled to a third port of said valve;

 a detector for monitoring a fluid level in said lumen; and

 wherein said valve is first operated to direct the circulating blood into said lumen to form a column of blood and wherein said valve is then operated to isolate said circulating blood from said lumen while coupling said lumen and said reservoir in fluid communication to form a falling column of blood in said lumen, said detector detecting the final position of said falling column of blood.

39. The apparatus of Claim 38 wherein said apparatus further comprises an overflow reservoir in fluid communication with said first reservoir through an aperture, said overflow reservoir collecting blood that exceeds a predetermined volume of blood in said reservoir from said falling column.

20 40. The apparatus of Claim 39 wherein said detector is positioned at a predetermined height above said aperture.

41. The apparatus of Claim 40 further comprising a processor for calculating the surface tension of the circulating blood according to the following:

$$\sigma = \frac{\rho d h g}{4},$$

where:

5 σ = surface tension (N/m)

ρ = blood density (g/m³)

d = lumen inside diameter (m);

h = the distance between said aperture and said final position of said falling column of blood (m); and

g = gravitational constant.

42. A method for determining whether a drug reduces or increases the surface tension of the circulating blood of a living being, said method comprising the steps of:

(a) determining the surface tension of the circulating blood of a living being utilizing a blood column height determinator based on capillary rise;

(b) administering a drug to the living being; and

(c) re-determining the surface tension of the circulating blood of the living being utilizing said blood column height determinator to see the change in the surface tension.

43. A method for improving blood perfusion to the lower extremities of a living being experiencing peripheral arterial disease, said method comprising the steps of:

(a) determining the viscosity of the circulating blood of the living being over a range of shear rates;

(b) reducing the viscosity of the circulating blood by administering a substance to the living being or by blood letting; and

(c) re-determining the viscosity of the circulating blood of the living being over said range of shear rates to verify said reduction in the viscosity.

5 44. An apparatus for determining the deformability of red blood cells of the circulating blood of a living being, said apparatus comprising a plurality of tubes closely adjacent one another and each having an inner diameter different from its neighbor, each of said plurality of tubes having an opening exposed to a flow of circulating blood and each of said tubes being closed at its other end for collecting red blood cells therein.

10 45. The apparatus of Claim 44 wherein said plurality of tubes are arranged sequentially from the smallest inner diameter to the largest inner diameter.

15 46. The apparatus of Claim 44 wherein the inner diameters of said plurality of tubes is within the range of 1 μ m to 10 μ m.

20 47. The apparatus of Claim 44 further comprising:

 an illuminator for passing light through each one of the plurality of tubes as they collect red blood cells in accordance with their respective inner diameters and wherein respective light rays, of varying degrees of redness corresponding to the amount of red blood cells collected in each of said plurality of tubes, emerge from said plurality of tubes; and

25 a redness color detector for detecting the degree of redness of each of said emerging light rays corresponding to each of said plurality of tubes.

48. An apparatus for detecting the lubricity of the circulating blood of a living being as the blood travels through the vascular system of the living being, said apparatus comprising:

(a) a transparent tube for passing a falling column of the circulating blood of the living being;

(b) an illuminator for directing light at a portion of said transparent tube that contains a residue left by said falling column;

(c) a detector for detecting any light that passes through the transparent tube and residue and generating corresponding detection data; and

(d) calculator for receiving said detection data and generating a lubricity value based on said detection data.

49. The apparatus of Claim 48 wherein said detector comprises a charge coupled device chip that generate pixel Gray scale values for said detection data.

50. The apparatus of Claim 49 wherein said calculation means comprises a processor and wherein said processor averages all of said pixel Gray scale values to generate said slipperyness value.

51. An apparatus for effecting the viscosity measurement of circulating blood in a living being, said apparatus comprising:

a lumen arranged to be coupled to the vascular system of the being;

a pair of tubes having respective first ends coupled to said lumen for receipt of circulating blood from the being, one of said pair of tubes comprising a capillary tube having some known parameters;

a valve for controlling the flow of circulating blood from the being's vascular system to said pair of tubes; and

an analyzer, coupled to said valve, for controlling said valve to permit the flow of blood into said pair of tubes whereupon the blood in each of said pair of tubes assumes a respective initial position with respect thereto, said analyzer also being arranged for operating said valve to isolate said pair of tubes from the being's vascular system and for coupling said pair of tubes together so that the position of the blood in said pair of tubes changes, said analyzer also being arranged for monitoring the blood position change in at least one of said tubes and calculating the viscosity of the blood based thereon, said analyzer comprising an indicator that generates an indication as to movement of the blood in at least one of said pair of tubes.

52. The apparatus of Claim 51 wherein said indicator comprises a flashing light whose flash rate is proportional to the movement of blood in at least one of said pair of tubes.

53. The apparatus of Claim 51 wherein said indicator comprises a speaker and a sound card that generate a sound having a frequency that is proportional to the movement of blood in at least one of said pair of tubes.

54. An apparatus for effecting the viscosity measurement of circulating blood in a living being, said apparatus comprising:

a lumen arranged to be coupled to the vascular system of the being;

a pair of tubes having respective first ends and second ends, said first ends being coupled together via a capillary tube having some known parameters;

5 a valve for controlling the flow of circulating blood from the being's vascular system to said pair of tubes, said valve being coupled to a second end of one of said pair of tubes and being coupled to said lumen; and

an analyzer, coupled to said valve, for controlling said valve to permit the flow of blood into said pair of tubes whereupon the blood in each of said pair of tubes assumes a respective initial position with respect thereto, said analyzer also being arranged for operating said valve to isolate said pair of tubes from the being's vascular system so that the position of the blood in said pair of tubes changes, said analyzer also being arranged for monitoring the blood position change in at least one of said tubes and calculating the viscosity of the blood based thereon, said analyzer comprising an indicator that generates an indication as to movement of the blood in at least one of said pair of tubes.

55. The apparatus of Claim 54 wherein said indicator comprises a flashing light whose flash rate is proportional to the movement of blood in at least one of said pair of tubes.


20 56. The apparatus of Claim 54 wherein said indicator comprises a speaker and a sound card that generate a sound having a frequency that is proportional to the movement of blood in at least one of said pair of tubes.

ABSTRACT

Various apparatus and methods for determining and utilizing the viscosity of the circulating blood of a living being over a range of shear rates for diagnostics and treatment such as detecting/reducing blood viscosity, work of the heart, contractility of the heart, for
5 detecting/reducing the surface tension of the blood, for detecting plasma viscosity, for explaining/countering endothelial cell dysfunction, for providing high and low blood vessel wall shear stress data, red blood cell deformability data, lubricity of blood, and for treating different ailments such as peripheral arterial disease.


24

FIG. 1A



- 24

FIG. 2A






FIG.3A




FIG.3B




FIG.3C




FIG.3D




FIG.3E

FIG. 4





FIG. 5A




FIG. 5B




FIG. 6

FIG. 7





FIG. 8









FIG.10



ABSOLUTE VS. EFFECTIVE VISCOSITY




FIG.11






FIG.13




FIG.14A





FIG.14B




FIG.14C

FIG.15






FIG.16A

FIG.16B

FIG.17



0923401-020100






FIG.20





FIG.21




FIG.22

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled APPARATUS & METHODS FOR COMPREHENSIVE BLOOD ANALYSIS, INCLUDING WORK OF, AND CONTRACTILITY OF, HEART AND THERAPEUTIC APPLICATIONS AND COMPOSITIONS THEREOF the specification of which is attached hereto unless the following box is checked:

Was filed on _____ as United States Application Number or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56. I hereby claim foreign priority benefits under 35 U. S. C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number _____ (Filing Date) _____

Application Number _____ (Filing Date) _____

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international date of this application.

<u>09/501,856</u>	<u>2/10/2000</u>	<u>Pending</u>
(Application Number)	(Filing Date)	(Status-patented, pending, abandoned)
<u>09/439,795</u>	<u>11/12/99</u>	<u>Pending</u>
(Application Number)	(Filing Date)	(Status-patented, pending, abandoned)
<u>09/919,906 (6,019,735)</u>	<u>8/28/97</u>	<u>Patented</u>
(Application Number)	(Filing Date)	(Status-patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Alan H. Bernstein (Registration No. 19,315); Stanley H. Cohen (Registration No. 20,235); Manny D. Pokotilow (Registration No. 22,492); Barry A Stein (Registration No. 25,257); Martin L. Faigus (Registration No. 24,364); Eric S. Marzluf (Registration No. 27,454); Robert S. Silver (Registration No. 35,681); Scott M. Slomowitz (Registration No. 39,032); Michael J. Berkowitz (Registration No. 39,607); David M. Tener (Registration No. 37,054); James J. Kozuch (Registration No. 39,733); Frank M. Linguiti (Registration No. 32,424); Gary A. Greene (Registration No. 38,897); Marilou Watson, (Registration No. 42,213) and Michael J. Cornelison (Registration No. 40,395) care of Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd., 12th Floor, Seven Penn Center, 1635 Market Street, Philadelphia, Pennsylvania 19103-2212, my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name) Kenneth Kensey

Inventor's signature [Signature] Date 7/27/00

Residence Chester Springs, PA Citizenship United States

Post Office Address 8 Hickory Lane, Chester Springs, PA 19425

Full name of second joint inventor, if any (given name, family name) William H. Hogenauer

Second Inventor's signature [Signature] Date 7/20/00

Residence Gilbertsville, PA Citizenship United States

Post Office Address 220 Jordan Drive, Gilbertsville, PA 19525

Additional inventors are being named on separately numbered sheets attached hereto. Yes

DECLARATION FOR PATENT APPLICATION

Full name of third inventor Young Cho

Inventor's Signature  Date 7/24/00

Residence _____ Citizenship United States

Post Office Address 132 Renaissance Drive, Cherry Hill, New Jersey 08003

007030-7043250